.Today is a big day for the regenerative medicine (RM) community in Ontario, Canada.
Minister of Research and Innovation, Reza Moridi, just announced that the Ontario Institute for Regenerative Medicine (OIRM) will receive a new $25 million commitment* (in addition to the $3.1 million committed in November 2014) to invest in translational research for degenerative diseases such as heart disease, autoimmune disorders, diabetes and vision loss. The Centre for Commercialization of Regenerative Medicine (CCRM), the commercialization partner for OIRM, will continue to seek opportunities to develop and commercialize the research being supported through OIRM.
Here’s a helpful infographic on moving Canadian stem cell research through the clinical trials process to become an approved medicine. It also features eight trials, seven of which are being led by OIRM researchers. If you’d like to delve further into one of these trials, you can read about Dr. Michael Fehlings’ (University Health Network) efforts to test the safety of neural stem cells used to regenerate thoracic and cervical spinal cord injuries.
*$25 million over five years
Our regular feature, Right Turn, appears every Friday and we invite you to submit your own blog to info(at)ccrm.ca. We encourage you to be creative and use the right (!) side of your brain. We dare you to make us laugh! Right Turn features cartoons, photos, videos and other content to amuse, educate and encourage discussion.
As always, we welcome your feedback in the comment section.
Latest posts by Stacey Johnson (see all)
- Right Turn: Vacationing on Mars - August 18, 2017
- Right Turn: Small device packs big potential - August 11, 2017
- BRM2017: State of the regenerative medicine industry - August 9, 2017